Non-Metastatic Esophageal Adenocarcinoma: Circulating Tumor Cells in the Course of Multimodal Tumor Treatment
Background: Isolation of circulating tumor cells (CTC) holds the promise to improve response-prediction and personalization of cancer treatment. In this study, we test a filtration device for CTC isolation in patients with non-metastatic esophageal adenocarcinoma (EAC) within recent multimodal treat...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/11/3/397 |
| _version_ | 1797708612163862528 |
|---|---|
| author | Jasmina Kuvendjiska Peter Bronsert Verena Martini Sven Lang Martha B. Pitman Jens Hoeppner Birte Kulemann |
| author_facet | Jasmina Kuvendjiska Peter Bronsert Verena Martini Sven Lang Martha B. Pitman Jens Hoeppner Birte Kulemann |
| author_sort | Jasmina Kuvendjiska |
| collection | DOAJ |
| description | Background: Isolation of circulating tumor cells (CTC) holds the promise to improve response-prediction and personalization of cancer treatment. In this study, we test a filtration device for CTC isolation in patients with non-metastatic esophageal adenocarcinoma (EAC) within recent multimodal treatment protocols. Methods: Peripheral blood specimens were drawn from EAC patients before and after neoadjuvant chemotherapy (FLOT)/chemoradiation (CROSS) as well as after surgery. Filtration using ScreenCell<sup>®</sup> devices captured CTC for cytologic analysis. Giemsa-stained specimens were evaluated by a cytopathologist; the cut-off was 1 CTC/specimen (6 mL). Immunohistochemistry with epithelial (pan-CK) and mesenchymal markers (vimentin) was performed. Results: Morphologically diverse malignant CTCs were found in 12/20 patients in at least one blood specimen. CTCs were positive for both vimentin and pan-CK. More patients were CTC positive after neoadjuvant therapy (6/20 vs. 9/15) and CTCs per/ml increased in most of the CTC-positive patients. After surgery, 8/13 patients with available blood specimens were still CTC positive. In clinical follow-up, 5/9 patients who died were CTC-positive. Conclusions: Detection of CTC by filtration within multimodal treatment protocols of non-metastatic EAC is feasible. The rate of CTC positive findings and the quantity of CTCs changes in the course of multimodal neoadjuvant chemoradiation/chemotherapy and surgery. |
| first_indexed | 2024-03-12T06:25:06Z |
| format | Article |
| id | doaj.art-907e9e07b653425ab07d1c42c185114a |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T06:25:06Z |
| publishDate | 2019-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-907e9e07b653425ab07d1c42c185114a2023-09-03T01:59:48ZengMDPI AGCancers2072-66942019-03-0111339710.3390/cancers11030397cancers11030397Non-Metastatic Esophageal Adenocarcinoma: Circulating Tumor Cells in the Course of Multimodal Tumor TreatmentJasmina Kuvendjiska0Peter Bronsert1Verena Martini2Sven Lang3Martha B. Pitman4Jens Hoeppner5Birte Kulemann6Department of General and Visceral Surgery, Medical Center—University of Freiburg, 79106 Freiburg, GermanyMedical Faculty, University of Freiburg, 79106 Freiburg, GermanyDepartment of General and Visceral Surgery, Medical Center—University of Freiburg, 79106 Freiburg, GermanyDepartment of General and Visceral Surgery, Medical Center—University of Freiburg, 79106 Freiburg, GermanyDepartment of Pathology & Andrew L. Warshaw, MD Institute for Pancreatic Cancer Research, Massachusetts General Hospital/Harvard Medical School, Boston, MA 02114, USADepartment of General and Visceral Surgery, Medical Center—University of Freiburg, 79106 Freiburg, GermanyDepartment of General and Visceral Surgery, Medical Center—University of Freiburg, 79106 Freiburg, GermanyBackground: Isolation of circulating tumor cells (CTC) holds the promise to improve response-prediction and personalization of cancer treatment. In this study, we test a filtration device for CTC isolation in patients with non-metastatic esophageal adenocarcinoma (EAC) within recent multimodal treatment protocols. Methods: Peripheral blood specimens were drawn from EAC patients before and after neoadjuvant chemotherapy (FLOT)/chemoradiation (CROSS) as well as after surgery. Filtration using ScreenCell<sup>®</sup> devices captured CTC for cytologic analysis. Giemsa-stained specimens were evaluated by a cytopathologist; the cut-off was 1 CTC/specimen (6 mL). Immunohistochemistry with epithelial (pan-CK) and mesenchymal markers (vimentin) was performed. Results: Morphologically diverse malignant CTCs were found in 12/20 patients in at least one blood specimen. CTCs were positive for both vimentin and pan-CK. More patients were CTC positive after neoadjuvant therapy (6/20 vs. 9/15) and CTCs per/ml increased in most of the CTC-positive patients. After surgery, 8/13 patients with available blood specimens were still CTC positive. In clinical follow-up, 5/9 patients who died were CTC-positive. Conclusions: Detection of CTC by filtration within multimodal treatment protocols of non-metastatic EAC is feasible. The rate of CTC positive findings and the quantity of CTCs changes in the course of multimodal neoadjuvant chemoradiation/chemotherapy and surgery.https://www.mdpi.com/2072-6694/11/3/397esophageal canceradenocarcinomacirculating tumor cellsmetastasischemotherapychemoradiationsurgery |
| spellingShingle | Jasmina Kuvendjiska Peter Bronsert Verena Martini Sven Lang Martha B. Pitman Jens Hoeppner Birte Kulemann Non-Metastatic Esophageal Adenocarcinoma: Circulating Tumor Cells in the Course of Multimodal Tumor Treatment Cancers esophageal cancer adenocarcinoma circulating tumor cells metastasis chemotherapy chemoradiation surgery |
| title | Non-Metastatic Esophageal Adenocarcinoma: Circulating Tumor Cells in the Course of Multimodal Tumor Treatment |
| title_full | Non-Metastatic Esophageal Adenocarcinoma: Circulating Tumor Cells in the Course of Multimodal Tumor Treatment |
| title_fullStr | Non-Metastatic Esophageal Adenocarcinoma: Circulating Tumor Cells in the Course of Multimodal Tumor Treatment |
| title_full_unstemmed | Non-Metastatic Esophageal Adenocarcinoma: Circulating Tumor Cells in the Course of Multimodal Tumor Treatment |
| title_short | Non-Metastatic Esophageal Adenocarcinoma: Circulating Tumor Cells in the Course of Multimodal Tumor Treatment |
| title_sort | non metastatic esophageal adenocarcinoma circulating tumor cells in the course of multimodal tumor treatment |
| topic | esophageal cancer adenocarcinoma circulating tumor cells metastasis chemotherapy chemoradiation surgery |
| url | https://www.mdpi.com/2072-6694/11/3/397 |
| work_keys_str_mv | AT jasminakuvendjiska nonmetastaticesophagealadenocarcinomacirculatingtumorcellsinthecourseofmultimodaltumortreatment AT peterbronsert nonmetastaticesophagealadenocarcinomacirculatingtumorcellsinthecourseofmultimodaltumortreatment AT verenamartini nonmetastaticesophagealadenocarcinomacirculatingtumorcellsinthecourseofmultimodaltumortreatment AT svenlang nonmetastaticesophagealadenocarcinomacirculatingtumorcellsinthecourseofmultimodaltumortreatment AT marthabpitman nonmetastaticesophagealadenocarcinomacirculatingtumorcellsinthecourseofmultimodaltumortreatment AT jenshoeppner nonmetastaticesophagealadenocarcinomacirculatingtumorcellsinthecourseofmultimodaltumortreatment AT birtekulemann nonmetastaticesophagealadenocarcinomacirculatingtumorcellsinthecourseofmultimodaltumortreatment |